摘要
目的分析对冠心病急性心肌梗死(心梗)伴心力衰竭(心衰)行经皮冠状动脉介入治疗(PCI)患者使用不同剂量阿托伐他汀治疗对其血清超敏C反应蛋白(hs-CRP)的影响。方法184例冠心病急性心梗伴心衰行PCI患者,随机分为研究组与对照组,各92例。研究组用大剂量阿托伐他汀治疗,对照组用常规剂量阿托伐他汀治疗。比较两组治疗效果、心功能临床指标[左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)]、hs-CRP、基质金属蛋白酶(MMP)、肌酸激酶同工酶(CK-MB)、肌钙蛋白T(cTnT)、同型半胱氨酸(Hcy)、胱抑素(CysC)、B型尿钠肽(BNP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、不良反应发生情况。结果研究组的治疗总有效率95.65%高于对照组的85.87%,差异有统计学意义(P<0.05)。术后1个月,研究组LVEDD、LVESD、LVEF分别为(58.64±10.63)mm、(49.69±9.84)mm、(55.23±10.23)%,均大于对照组的(47.89±9.46)mm、(40.13±9.86)mm、(49.93±9.97)%,差异有统计学意义(P<0.05)。术后1个月,研究组hs-CRP、MMP、CK-MB、cTnT均优于对照组,差异有统计学意义(P<0.05)。研究组Hcy、CysC、BNP、IL-6、TNF-α均优于对照组,差异有统计学意义(P<0.05)。结论冠心病急性心梗伴心衰行PCI患者使用大剂量的阿托伐他汀可有效改善心功能水平及临床各项指标,且安全可靠,具有临床应用的价值和意义。
Objective To analyze the effect of different doses of atorvastatin on serum hypersensitivity C-reactive protein(hs-CRP)in patients with coronary heart disease,acute myocardial infarction and heart failure undergoing percutaneous coronary intervention(PCI).Methods A total of 184 patients with coronary heart disease,acute myocardial infarction and heart failure undergoing PCI were randomly divided into research group and control group,with 92 cases in each group.The research group was treated with high-dose atorvastatin,and the control group was treated with regular dose atorvastatin.The therapeutic effect,clinical indexes of cardiac function[left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF)],hs-CRP,matrix metalloproteinase(MMP),creatine kinase isoenzyme(CK-MB),cardiac troponin T(cTnT),homocysteine(Hcy),cystatin C(Cys C),B-type natriuretic peptide(BNP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and occurrence of adverse reactions were compared between the two groups.Results The total effective rate 95.65%of the research group was higher than 85.87%of the control group,and the difference was statistically significant(P<0.05).1 month after operation,the LVEDD,LVESD and LVEF of the research group were(58.64±10.63)mm,(49.69±9.84)mm and(55.23±10.23)%of the research group were greater than(47.89±9.46)mm,(40.13±9.86)mm and(49.93±9.97)%of the control group,and the difference was statistically significant(P<0.05).1 month after operation,the hs-CRP,MMP,CKMB and cTnT of the research group were better than those of the control group,and the difference was statistically significant(P<0.05).The Hcy,CysC,BNP,IL-6 and TNF-αof the research group were better than those of the control group,and the difference was statistically significant(P<0.05).Conclusion High-dose atorvastatin shows remarkable effect on patients with coronary heart disease,acute myocardial infarction and heart failure undergoing PCI,and it can effectively improve the cardiac function and clinical indicators.It is safe and reliable,and has the value and significance of clinical application.
作者
梁国泉
陈安
范火珍
李思明
杨清梅
罗剑静
LIANG Guo-quan;CHEN An;FAN Huozhen(Department of Cardiology,Second People’s Hospital,Zhaoqing 526000,China)
出处
《中国现代药物应用》
2021年第10期4-7,共4页
Chinese Journal of Modern Drug Application
基金
2017年肇庆市科技创新指导类项目(项目编号:201704030709)。
关键词
冠心病
急性心肌梗死
心力衰竭
经皮冠状动脉介入治疗
阿托伐他汀
超敏C反应蛋白
Coronary heart disease
Acute myocardial infarction
Heart failure
Percutaneous coronary intervention
Atorvastatin
Hypersensitivity C-reactive protein
